Description

We propose to perform a randomized phase II clinical trial in patients
with oligometastatic non-small-cell lung cancer (NSCLC). NSCLC patients
are eligible for this clinical trial when failed to respond or progress on
anti-PD-1 therapy (pembrolizumab, with or without cytotoxic
chemotherapy).
AcronymFWOTBM3
StatusActive
Effective start/end date1/10/1930/09/23

    Flemish discipline codes

  • Clinical trials

    Research areas

  • NSCLC

ID: 49389753